Stocks Health care CGON
NASDAQ · Health careCG Oncology, Inc. (CGON)
CG Oncology, Inc. brought in $6.2M of revenue over the twelve months to September 30, 2026, up 183.6% from a year earlier. It posted a net loss of $237.5M. In fiscal 2025 capital spending exceeded operating cash flow by $132.5M. At September 30, 2026 it held $28.2M in cash against $3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about CG Oncology, Inc.
- Net worth
- CG Oncology, Inc. has a market value (market cap) of $6.4B at the latest share price, and shareholders' equity of $991M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4M (+254.7% year on year), with a net loss of $161M. Over the 12 months to September 30, 2026: revenue $6.2M, net loss $237.5M.
- Cash flow
- In fiscal 2025 operations used $132.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- CG Oncology, Inc.'s next report is expected around February 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What CG Oncology, Inc. does
CG Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4M | -$161M | -$2.08 | -$132.5M |
| 2024 | $1.1M | -$88M | -$1.41 | -$78.9M |
| 2024 | $204K | -$48.6M | -$15.65 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CGON ranks in Health care
Latest SEC filings
What CG Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 3.7% to $1.6M versus the same quarter last year; diluted EPS -$0.64 versus -$0.57.
- November 6, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
- May 26, 2026
Insider trades
What the people running CG Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $209.6K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Post Leonard EDirector | Exercised options | 1,000 | $600 |
| October 15, 2026 | Post Leonard EDirector | Soldpre-planned (10b5-1) | 500 | $30.8K |
| October 15, 2026 | Post Leonard EDirector | Soldpre-planned (10b5-1) | 500 | $31.2K |
| September 15, 2026 | Post Leonard EDirector | Exercised options | 1,000 | $600 |
| September 15, 2026 | Post Leonard EDirector | Soldpre-planned (10b5-1) | 1,000 | $73K |
| August 14, 2026 | Post Leonard EDirector | Exercised options | 1,000 | $600 |
| August 14, 2026 | Post Leonard EDirector | Soldpre-planned (10b5-1) | 1,000 | $74.5K |
| July 15, 2026 | Post Leonard EDirector | Exercised options | 1,000 | $600 |
Who owns CGON
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RTW Investments, LP13G, passive with 1 related filers | 9.7% | August 14, 2026 |
| Xiangmin Cui13G, passive with 4 related filers | 8.4% | February 14, 2025 |
| T. Rowe Price Investment Management, Inc.13G, passive | 8% | May 15, 2026 |
| Patrick G. Enright13D, may seek influence with 5 related filers | 6% | September 18, 2025 |
| Wellington Management Group LLP13G, passive with 3 related filers | 6% | August 13, 2026 |
| SONG, Hong Fang13G, passive with 9 related filers | 5.5% | January 28, 2025 |
| Fmr LLC13G, passive with 1 related filers | 5.1% | August 6, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 227 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 8,514,590 | +1,529,782 |
| Decheng Capital LLC | 6,371,669 | 0 |
| BlackRock, Inc. | 6,256,288 | +1,192,108 |
| Wellington Management Group Llp | 5,324,751 | -46,481 |
| Fmr LLC | 4,161,493 | +396,649 |
| TCG Crossover Management, LLC | 3,670,206 | 0 |
| Vanguard Portfolio Management LLC | 3,465,197 | +370,099 |
| State Street Corp | 3,437,590 | +790,536 |
| Vanguard Capital Management LLC | 3,316,793 | +283,168 |
| Foresite Capital Management VI LLC | 2,369,574 | +148,100 |
| Geode Capital Management, LLC | 2,153,277 | +556,413 |
| Seven Fleet Capital Management LP | 1,886,236 | +1,810,478 |
| EcoR1 Capital, LLC | 1,494,300 | +392,300 |
| DV Trading LLC | 1,439,393 | 0 |
| Avidity Partners Management LP | 1,398,948 | +110,000 |
| Franklin Resources Inc | 1,312,880 | -194,125 |
| Alliancebernstein L.P. | 1,374,149 | +84,062 |
| Morgan Stanley | 1,177,109 | +656,896 |
| Acorn Capital Advisors, LLC | 1,131,500 | +999 |
| Foresite Capital Management V, LLC | 1,079,050 | +75,000 |
Insiders
2 insiders reported holding 2,085,152 shares in total, about $151.5M at the last price.
| Holder | Shares |
|---|---|
| Liu Brian Guan-ChyunDirector | 1,886,2361,886,236 held indirectly |
| Kuan ArthurChief Executive Officer, Director | 198,916 |
Questions about CGON
What does CG Oncology, Inc. do?
CG Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as CGON. Its shares trade on NASDAQ under the ticker CGON.
What is CG Oncology, Inc.'s net worth?
CG Oncology, Inc. has a market value (market cap) of $6.4B at the latest share price, and shareholders' equity of $991M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CG Oncology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $237.5M on revenue of $6.2M.
How much revenue does CG Oncology, Inc. make?
Over the twelve months to September 30, 2026 CG Oncology, Inc. reported revenue of $6.2M. That is 183.6% more than a year earlier.
When did CG Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is CG Oncology, Inc.'s next earnings report?
CG Oncology, Inc.'s next report is expected around February 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CGON with
Follow CGON
Get an email when CG Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CG Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.